CombinAble.AI

Company Overview

Snapshot

Founded in August 2023 by Daria Kokh, CombinAble.AI operates with 1–10 employees. The company was acquired by insitro in January 2026, marking a significant milestone in its trajectory.

Business overview

CombinAble.AI develops an AI platform for therapeutic design, focusing on the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers. This technology aims to accelerate the development of best-in-class therapeutics, serving the biopharmaceutical, biotechnology, and pharmaceutical industries within the Health Tech & Life Sciences sector.

Strategic signal

The acquisition of CombinAble.AI by insitro in January 2026 signals a strong validation of its AI-driven approach to drug discovery and design. This move indicates a strategic consolidation within the life sciences sector, as larger players integrate advanced AI capabilities to enhance their R&D pipelines and accelerate therapeutic development.

Company Intelligence Q&A

What is CombinAble.AI's primary focus?

CombinAble.AI focuses on developing an AI platform for the rapid in silico design and optimization of complex antibody therapeutics, including bi-specifics, tri-specifics, and T-cell engagers.

When was CombinAble.AI founded?

CombinAble.AI was founded in August 2023.

Who acquired CombinAble.AI?

CombinAble.AI was acquired by insitro in January 2026.

What was a key early development for CombinAble.AI?

In March 2024, AION Labs launched CombinAble.AI, aiming to reduce the time and cost associated with targeted antibody design and optimize drug development.

Who is the founder of CombinAble.AI?

Daria Kokh is the Co-founder & CEO of CombinAble.AI.